MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

PM · NYSE

Philip Morris International Inc

Health Care · Medicinal Chemicals and Botanical Products

Reference price$194.41As of Jul 30, 2026
Market capitalization$303B
52-week range$142.11–$207.76
S&P 500 portfolio weight0.49%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$175.00-10.0% vs. reference
Average$209.20+7.6% vs. reference
High$225.00+15.7% vs. reference
7 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$2.244 estimates
Expected range$2.23–$2.26Low to high EPS
Dec 2026$8.33Street EPS consensus
Dec 2027$9.16Street EPS consensus
Dec 2028$10.12Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+7.3% YoY$40.65B$37.88B
Operating income$14.89B$13.4B
Net income$11.35B$7.06B
Operating cash flow$12.23B$12.22B
Capital expenditures($1.57B)($1.44B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

BNK Invest

Tuesday Sector Leaders: Cigarettes & Tobacco, Paper & Forest Products

RTTNews

PMI Launches $1.2B Aurora Facility, Expands ZYN Production

BNK Invest

ACWI, PM, GEV, C: Large Outflows Detected at ETF

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.